Draft:Barrett E. Rabinow
American pharmaceutical scientist
From Wikipedia, the free encyclopedia
Barrett E. Rabinow is an American pharmaceutical scientist whose work has focused on pharmaceutical formulation, nanosuspensions, nanoparticle drug delivery, parenteral dosage forms, and injectable drug products. He worked for Baxter Healthcare Corporation, where he held the title of Baxter Distinguished Scientist.[1][2]
 | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 4,708 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 17 May 2026 by ChrysGalley (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
Submission declined on 11 May 2026 by Gurkubondinn (talk). This draft reads like a resume or curriculum vitae. Wikipedia is an encyclopedia, not a professional networking website or a place to promote yourself or your services. We also strongly discourage writing about yourself.
Articles about people must meet Wikipedia's criteria for inclusion for people. The draft requires multiple published secondary sources that:
This draft's references do not show that the person meets Wikipedia's criteria for inclusion for people. The draft requires multiple published secondary sources that:
Declined by Gurkubondinn 43 days ago.
| |
Comment: Unchecked LLM. ChrysGalley (talk) 10:35, 17 May 2026 (UTC)
Rabinow is associated with the development and study of nanosuspension based drug delivery, a formulation approach used for drugs with poor water solubility. His 2004 review article, "Nanosuspensions in drug delivery", published in Nature Reviews Drug Discovery, reviewed the use of nanosuspensions for drug candidates that are difficult to formulate by conventional methods.[3] Later review literature on nanosuspensions and drug nanocrystals has cited the article in discussions of formulation strategies for improving dissolution, apparent solubility, and bioavailability of poorly water soluble drugs.[4][5]
Biography
Rabinow received an A.B. from Cornell University in 1968 and a Ph.D. in chemistry from the University of Chicago in 1974.[6] He joined Baxter Healthcare in 1977 and remained associated with the company for much of his career.[1][2]
Public sources describe Rabinow primarily through his scientific work rather than through personal biographical coverage. His published research is situated within pharmaceutical formulation, especially the problem of developing usable dosage forms for drug compounds that have limited solubility or require specialized delivery systems. In that area, nanosuspensions were studied as one way to administer compounds that could not easily be prepared as ordinary solutions.[3][4][5]
Scientific work
Rabinow's work has addressed formulation problems involving poorly water soluble drugs, injectable suspensions, and particle based delivery systems. His 2004 article in Nature Reviews Drug Discovery described nanosuspensions as colloidal dispersions of drug particles stabilized by surfactants. The article discussed nanosuspensions as a formulation method for compounds where other solubilization approaches were limited.[3]
Rabinow and coauthors later studied specific nanosuspension formulations. In 2007, he coauthored a study of an intravenous itraconazole nanosuspension in the International Journal of Pharmaceutics.[7] He also coauthored a review in Advanced Drug Delivery Reviews on suspensions for intravenous injection, covering development, preclinical, and clinical considerations for injectable suspension products.[8]
Rabinow was also involved in research on nanoparticle based antiretroviral delivery. A 2006 article in Blood, on which he was a coauthor, reported on a macrophage based nanoparticle platform for antiretroviral drug delivery.[9] He was also a coauthor of a 2009 PLOS ONE study concerning monocyte macrophage uptake and tissue distribution of superparamagnetic iron oxide nanoparticles.[10]
Additional research by Rabinow and coauthors has concerned pharmacokinetics of nanosuspension administered drugs, paclitaxel nanosuspensions, itraconazole formulation, and ropivacaine microparticle suspensions.[11][12][13][14]
Patents
Rabinow is listed as an inventor on United States patents and patent applications concerning drug delivery, nanoparticle formulations, antimicrobial formulations, antineoplastic agents, cardiac drug administration, and biomaterials.[15] His issued patents include inventions titled "Compositions and methods for drug delivery", "Method for delivering drugs to the brain", "Method for treating infectious organisms normally considered to be resistant to an antimicrobial drug", "Method for preparing submicron particles of antineoplastic agents", and "Biomaterials with hydrophilic surfaces".[15]
Selected publications
- Rabinow, Barrett E. "Nanosuspensions in drug delivery." Nature Reviews Drug Discovery. 2004;3(9):785–796.[3]
- Rabinow, Barrett. "Pharmacokinetics of drugs administered in nanosuspension." Discovery Medicine. 2005;5(25):74–79.[11]
- Dou, Huanyu; Destache, Christopher J.; Morehead, Justin R.; et al. "Development of a macrophage based nanoparticle platform for antiretroviral drug delivery." Blood. 2006;108(8):2827–2835.[9]
- Rabinow, Barrett; Kipp, James; Papadopoulos, Pavlos; et al. "Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat." International Journal of Pharmaceutics. 2007;339(1–2):251–260.[7]
- Wong, Joseph; Brugger, Andrew; Khare, Atul; et al. "Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects." Advanced Drug Delivery Reviews. 2008;60(8):939–954.[8]
- Beduneau, Aurore; Saulnier, Patrick; Benoit, Jean-Pierre; et al. "Facilitated Monocyte-Macrophage Uptake and Tissue Distribution of Superparamagnetic Iron-Oxide Nanoparticles." PLOS ONE. 2009;4(2):e4343.[10]
- McKee, Jeff; Rabinow, Barrett; Cook, Chyung; Gass, Jerry. "Nanosuspension formulation of itraconazole eliminates the negative inotropic effect observed in guinea pig atria." International Journal of Pharmaceutics. 2010;395(1–2):281–289.[12]
- Lee, Sarah E.; Rabinow, Barrett; et al. "Paclitaxel nanosuspensions for targeted chemotherapy." Nanomedicine. 2014.[13]
LLM-generated pages with certain obvious signs of being machine generated may be deleted without notice.
These tools are prone to specific issues that violate our policies:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject.
See the advice page on large language models for more information.